Analystreport

Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com